- Home
- SPRY vs MDXG Comparison
SPRY vs MDXG Comparison
Compare SPRY & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- MDXG
- Stock Information
- Founded
- SPRY 2015
- MDXG 2006
- Country
- SPRY United States
- MDXG United States
- Employees
- SPRY N/A
- MDXG N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- SPRY Health Care
- MDXG Health Care
- Exchange
- SPRY Nasdaq
- MDXG Nasdaq
- Market Cap
- SPRY 1.1B
- MDXG 1.1B
- IPO Year
- SPRY N/A
- MDXG N/A
- Fundamental
- Price
- SPRY $12.57
- MDXG $9.12
- Analyst Decision
- SPRY Strong Buy
- MDXG Strong Buy
- Analyst Count
- SPRY 4
- MDXG 5
- Target Price
- SPRY $26.00
- MDXG $12.00
- AVG Volume (30 Days)
- SPRY 1.5M
- MDXG 674.7K
- Earning Date
- SPRY 11-13-2024
- MDXG 02-26-2025
- Dividend Yield
- SPRY N/A
- MDXG N/A
- EPS Growth
- SPRY N/A
- MDXG N/A
- EPS
- SPRY N/A
- MDXG 0.52
- Revenue
- SPRY $2,568,000.00
- MDXG $342,804,000.00
- Revenue This Year
- SPRY $66,750.00
- MDXG $9.56
- Revenue Next Year
- SPRY $508.63
- MDXG $9.19
- P/E Ratio
- SPRY N/A
- MDXG $18.12
- Revenue Growth
- SPRY 8460.00
- MDXG 10.93
- 52 Week Low
- SPRY $6.00
- MDXG $5.47
- 52 Week High
- SPRY $18.51
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- SPRY 58.86
- MDXG 53.35
- Support Level
- SPRY $11.00
- MDXG $8.50
- Resistance Level
- SPRY $12.48
- MDXG $9.71
- Average True Range (ATR)
- SPRY 0.81
- MDXG 0.30
- MACD
- SPRY 0.28
- MDXG -0.04
- Stochastic Oscillator
- SPRY 84.95
- MDXG 51.24
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.